Bayer's $11 Mil. Oncogene Purchase Adds Oncology Diagnostics Stable
This article was originally published in The Gray Sheet
Executive Summary
Bayer's acquisition of OSI Pharmaceuticals' diagnostic business builds on the firms' collaborative efforts to run OSI's HER-2/neu breast cancer assay on Bayer's Technicon Immuno I automated immunoassay.